5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine
- Product Name
- 5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine
- CAS No.
- 1000787-75-6
- Chemical Name
- 5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine
- Synonyms
- GS 9190;GS 333126;Tegobuvir;9190/tegobuvir;GS-9190|||GS 333126;Tegobuvir (GS-9190);Tegobuvir, 10 mM in DMSO;GS9190; GS 333126; GS 9190; GS-333126; GS333126;GS 333126;GS 9190;GS-333126;GS-9190;GS333126;GS9190;5-[[6-[2,4-Bis(trifluoromethyl)phenyl]-3-pyridazinyl]methyl]-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine
- CBNumber
- CB22598507
- Molecular Formula
- C25H14F7N5
- Formula Weight
- 517.4
- MOL File
- 1000787-75-6.mol
5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine Property
- Boiling point:
- 558.0±60.0 °C(Predicted)
- Density
- 1.46
- storage temp.
- Store at -20°C
- solubility
- ≥24.95 mg/mL in DMSO; insoluble in H2O; ≥100 mg/mL in EtOH
- form
- solid
- pka
- 8.28±0.20(Predicted)
- color
- White to off-white
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P270Do not eat, drink or smoke when using this product.
P271Use only outdoors or in a well-ventilated area.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P302+P352IF ON SKIN: wash with plenty of soap and water.
P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P321Specific treatment (see … on this label).
P330Rinse mouth.
P332+P313IF SKIN irritation occurs: Get medical advice/attention.
P337+P313IF eye irritation persists: Get medical advice/attention.
P403+P233Store in a well-ventilated place. Keep container tightly closed.
P405Store locked up.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- CS-0672
- Product name
- Tegobuvir
- Purity
- 98.52%
- Packaging
- 5mg
- Price
- $350
- Updated
- 2021/12/16
- Product number
- A3864
- Product name
- Tegobuvir
- Packaging
- 10mM(in 1mL DMSO)
- Price
- $390
- Updated
- 2021/12/16
- Product number
- A3864
- Product name
- Tegobuvir
- Packaging
- 10mg
- Price
- $475
- Updated
- 2021/12/16
- Product number
- API0013922
- Product name
- GS-333126
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $497.13
- Updated
- 2021/12/16
- Product number
- CS-0672
- Product name
- Tegobuvir
- Purity
- 98.52%
- Packaging
- 10mg
- Price
- $600
- Updated
- 2021/12/16
5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine Chemical Properties,Usage,Production
Biological Activity
Tegobuvir (GS-9190; TGV) is an orally active, non-cytotoxic imidazopyridine that, upon CYP-mediated intracellular activation, forms a glutathione conjugate th at acts as a covalent, potent and genotype 1 replicons-selective non-nucleoside inhibitor (NNI) against hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (IC50 = 0.8 nM/1b, 13.8 nM/1a, 21.9 μM/2a, >50 μM/1a; IC50 >100 nM against 2b, 3a, 4a, 5a, and 6a). When combined with suboptimal concentrations of other direct acting antivirals (DAAs) in cultures, tegobuvir (6-30 nM) is highly effective in curing cells from HCV replicon and in delaying or preventing the development of resistance against other DAAs.
References
[1]. zeuzem s, andreone p, pol s, lawitz e, diago m, roberts s, focaccia r, younossi z, foster gr, horban a et al: telaprevir for retreatment of hcv infection. n engl j med 2011, 364(25):2417-2428.
[2]. wong ka, xu s, martin r, miller md, mo h: tegobuvir (gs-9190) potency against hcv chimeric replicons derived from consensus ns5b sequences from genotypes 2b, 3a, 4a, 5a, and 6a. virology 2012, 429(1):57-62.
[3]. shih ih, vliegen i, peng b, yang h, hebner c, paeshuyse j, purstinger g, fenaux m, tian y, mabery e et al: mechanistic characterization of gs-9190 (tegobuvir), a novel nonnucleoside inhibitor of hepatitis c virus ns5b polymerase. antimicrob agents chemother 2011, 55(9):4196-4203.
[4]. behrens se, tomei l, de francesco r: identification and properties of the rna-dependent rna polymerase of hepatitis c virus. embo j 1996, 15(1):12-22.
[5]. hebner cm, han b, brendza km, nash m, sulfab m, tian y, hung m, fung w, vivian rw, trenkle j et al: the hcv non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit ns5b polymerase function. plos one 2012, 7(6):e39163.
5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine Preparation Products And Raw materials
Raw materials
Preparation Products
5-((6-(2,4-bis(TrifluoroMethyl)phenyl)pyridazin-3-yl)Methyl)-2-(2-fluorophenyl)-5H-iMidazo[4,5-c]pyridine Suppliers
- Tel
- +1-800-259-7612
- Fax
- +1-800-259-7612
- info@musechem.com
- Country
- United States
- ProdList
- 4660
- Advantage
- 60
- Tel
- +1-781-999-5354 +1-00000000000
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32161
- Advantage
- 58
- Tel
- Fax
- 1-516-927-0118
- Info@alfa-chemistry.com
- Country
- United States
- ProdList
- 24072
- Advantage
- 58
- Tel
- +1-+1(833)-552-7181
- sales@aladdinsci.com
- Country
- United States
- ProdList
- 52924
- Advantage
- 58
- Tel
- --
- Fax
- --
- sales@apexbt.com
- Country
- United States
- ProdList
- 6251
- Advantage
- 58
- Tel
- --
- Fax
- --
- cayman@caymanchem.com
- Country
- United States
- ProdList
- 6213
- Advantage
- 81
- Tel
- --
- Fax
- --
- admin@intlab.org
- Country
- United States
- ProdList
- 5356
- Advantage
- 50